COMMUNIQUÉS West-GlobeNewswire

Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
07/10/2026
ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has defined as supportive of potential approval Atsena also reported new data [...]
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
07/10/2026
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative [...]
Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
07/10/2026
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia [...]
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
07/10/2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that [...]
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
07/10/2026
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira [...]
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
07/10/2026
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no [...]
BrewDog Rallies Beer Lovers Across the UK to Choose Craft
07/10/2026
Bold UK-wide campaign puts craft beer back at the centre of culture, celebrating better ingredients, better quality, skilled brewers, beer lovers and the big flavours that make craft worth choosing. BrewDog consumers [...]
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
07/10/2026
– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today [...]
Vystar Announces Formation of New R3ALM Corporation and Progress Toward Live Platform Launch
07/10/2026
Company Advances R3ALM Ecosystem Toward Commercial Launch and Announces Multiple Tokenization Projects BOSTON, MA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST) today announced that, following the [...]
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
07/10/2026
NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson & Johnson, and Genmab and AbbVie. DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ( www. [...]
AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
07/10/2026
CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development Access the article here OCALA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech [...]
Optimi Health to Present at the ThinkEquity Conference
07/10/2026
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“ Optimi ” or “the Company ”), a commercial-stage pharmaceutical manufacturer and clinical-stage [...]
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
07/10/2026
SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Integrity Care Group Enters Two New States and Strengthens Core Market with Acquisition of 15 NextCare Clinics; Now Offers Access to High-Quality Healthcare in 100 Clinics Across Five States
07/10/2026
The acquisition follows the recent unification of Xpress Wellness and Integrity Urgent Care under a single masterbrand – Integrity Care Group Key facts of this press release: Integrity Care Group acquired 15 NextCare [...]
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
07/10/2026
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications BIO-Europe provides a key platform to advance ongoing discussions and [...]
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
07/10/2026
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of [...]
Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program
07/10/2026
LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their [...]
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
07/10/2026
Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder Vancouver, Canada, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Commure Appoints Nick Apeland as President of Go-to-Market
07/10/2026
Healthcare veteran Nick Apeland to lead Commure’s Go-to-Market at a time of rapid growth for the business, now serving over 500 health systems and practices Former Revenue leader who built and scaled Qualtrics [...]

Pages